Development of an immobilized Mycobacterium tuberculosis purine nucleoside phosphorylase platform for ligand fishing and inhibition assays
Journal of Pharmaceutical and Biomedical Analysis · 2025
DOI: 10.1016/j.jpba.2024.116576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2025. Verfasst von Isabella Sant'Anna und 4 weiteren Autor:innen. Beteiligte Einrichtung: BioCrom, Instituto de Química, Departamento de Química Orgânica, Universidade Federal Fluminense, Niterói 24020-141, Brazil. Hauptthemen laut MEDLINE: Purine-Nucleoside Phosphorylase, Mycobacterium tuberculosis, Enzymes, Immobilized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Purine nucleoside phosphorylase (PNP) from Mycobacterium tuberculosis (MtPNP) plays a crucial role in purine metabolism, making it an attractive target for developing new tuberculosis treatments. In this study, we developed a ligand screening platform using MtPNP covalently immobilized on magnetic particles (MtPNP-MPs). The immobilization process achieved a high enzyme loading and preserved the enzyme catalytic activity, enabling its use in both activity and affinity-based screening assays. The activity of MtPNP-MPs was monitored by quantifying hypoxanthine released from inosine phosphorolysis, and kinetic studies revealed Michaelis-Menten behavior for inosine and inorganic phosphate substrates, with KM values comparable to those of free MtPNP. A proof-of-concept inhibitor study using the transition state analog DI4G demonstrated the platform capability for recognizing and characterizing inhibitors, yielding an IC50 value of 91.4 nM and a competitive inhibition mechanism with a Ki of 69.2 nM. Furthermore, the MtPNP-MPs exhibited high stability, retaining over 80 % of their activity after six months of storage and more than 90 % after five consecutive reaction cycles, highlighting their potential for reuse in high-throughput assays. We optimized key parameters for ligand fishing assay, including the amount of MtPNP-MPs, incubation time, and elution conditions. While higher organic solvent concentrations and longer elution times improved ligand isolation, these conditions also reduced enzyme activity. This trade-off between ligand isolation yield and enzyme reusability suggests that elution conditions should be tailored based on the ligand binding strength. Overall, this study establishes the MtPNP-MPs platform as a versatile tool for ligand identification and inhibitor characterization, with promising applications in the screening of complex libraries, such as natural products, for bioactive compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioCrom, Instituto de Química, Departamento de Química Orgânica, Universidade Federal Fluminense, Niterói 24020-141, Brazil.
- BioCrom, Instituto de Química, Departamento de Química Orgânica, Universidade Federal Fluminense, Niterói 24020-141, Brazil. Electronic address: mcmoraes@id.uff.br.
Zitieren
APA
Sant'Anna, I., Arêdes, R. S., de Souza, W. C. P., Lessa, R. C. D. S., & de Moraes, M. C. (2025). Development of an immobilized Mycobacterium tuberculosis purine nucleoside phosphorylase platform for ligand fishing and inhibition assays. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2024.116576
Vancouver
Sant'Anna I, Arêdes RS, de Souza WCP, Lessa RCDS, de Moraes MC. Development of an immobilized Mycobacterium tuberculosis purine nucleoside phosphorylase platform for ligand fishing and inhibition assays. Journal of Pharmaceutical and Biomedical Analysis. 2025. doi:10.1016/j.jpba.2024.116576
BibTeX
@article{SantAnna2025,
author = {Sant'Anna, Isabella and Arêdes, Rafaella Silva and de Souza, Walter Claudino P and Lessa, Renato Corrêa da Silva and de Moraes, Marcela Cristina},
title = {Development of an immobilized Mycobacterium tuberculosis purine nucleoside phosphorylase platform for ligand fishing and inhibition assays},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2025},
doi = {10.1016/j.jpba.2024.116576}
}
EUVIMED